HSV-tk gene therapy in head and neck squamous cell carcinoma: Enhancement by the local and distant bystander effect

Archives of Otolaryngology - Head and Neck Surgery

Volumn 122, Issue 7, 1996, Pages 746-749

  Wilson, Keith M ^a   Stambrook, Peter J ^b   Bi, Wan Li ^b   Pavelic, Zlatko P ^a   Pavelic, Ljiljana ^a   Gluckman, Jack L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS ENZYME;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GENETIC TRANSDUCTION; HEAD AND NECK CARCINOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION;

EID: 0030000923     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1996.01890190042011     Document Type: Article

References (15)

1. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in generation of an anti-tumor response. Cell. 1990; 60:397-403.
2. Gansbacher B, Zier K, Danniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;1722:1217-1224.
3. Rosenberg SA, Aerbersold P, Cornetta K, et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990; 323:570-578.
4. Weber JS, Rosenberg SA. Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor infiltrating lymphocytes. J Natl Cancer Res. 1990;82:755-761.
5. Asher AL, Mule JJ, Kasid A, et al. Murine tumor cells transduced with the gene of tumor necrosis factor against tumors. J Immunol. 1991;146:3227-3234.
6. Culver KW, Ram Z, Walbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
7. Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy on malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res. 1992;33:493-503.
8. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML. Treatment and prevention of rat glioblastoma by immunogenic c6 cells expressing antisense insulin-like growth factor I RNA. Science. 1993;259:94-97.
9. Karp SE, Hwu P, Farber A, et al. In vivo activity of tumor necrosis factor (TNF) mutants: secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. J Immunol. 1992;149:2076-2081.
10. Moolten FL, Wells JM. Curability of tumors bearing herpes simplex virus thymidine kinase and potent antiherpetic activity of 2′- nor -2′ deoxyguanosine (2′NDG). Biochem Biophys Res Commun. 1982;108:1716-1721.
11. Ram Z, Culver KW, Walbridge R, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993;53:83-88.
12. Cheng YC, Grill SP, Dutschman GE, Nakayama K, Bastow KR. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem. 1983;258:12460-12464.
13. Bi LW, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
14. Dziarski R. Opposing effects of xid and nu mutations on proliferative and polyclonal antibody and autoantibody responses to peptidoglycan, LPS, protein A and PWM. Immunology. 1984;53:563-574.
15. Sharp AK, Colston MJ. Elevated macrophage activity in nude mice. Exp Cell Biol. 1984;52:44-47.